Antineoplastic agents and thrombotic microangiopathy

J Oncol Pharm Pract. 2017 Mar;23(2):135-142. doi: 10.1177/1078155216628324. Epub 2016 Jun 23.

Abstract

Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.

Keywords: Chemotherapy; hemolytic uremic syndrome; thrombotic microangiopathy; thrombotic thrombocytopenic purpura.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Gemcitabine
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use
  • Incidence
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use
  • Mitomycin / adverse effects
  • Mitomycin / therapeutic use
  • Molecular Targeted Therapy / adverse effects*
  • Neoplasms / drug therapy*
  • Proteasome Inhibitors / adverse effects
  • Proteasome Inhibitors / therapeutic use
  • Signal Transduction / drug effects
  • Thrombotic Microangiopathies / chemically induced*
  • Thrombotic Microangiopathies / epidemiology
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Antineoplastic Agents
  • Immunologic Factors
  • Interferon-alpha
  • Proteasome Inhibitors
  • Vascular Endothelial Growth Factor A
  • Deoxycytidine
  • Mitomycin
  • Gemcitabine